Baker Bros. Advisors added 2,005,813 shares of Kymera Therapeutics; the estimated transaction value was $135.45 million.
Meanwhile, the quarter-end position value increased by $297.15 million, reflecting both new purchases and share price moves.
The post-trade stake stood at 8,657,242 shares valued at $673.62 million.
Baker Bros. Advisors reported a buy of 2,005,813 Kymera Therapeutics (NASDAQ:KYMR) shares in its February 17, 2026, SEC filing, an estimated $135.45 million trade based on quarterly average pricing.
According to a February 17, 2026 SEC filing, Baker Bros. increased its holding in Kymera Therapeutics (NASDAQ:KYMR) by 2,005,813 shares. The estimated trade value was $135.45 million, based on the average closing price during the fourth quarter of 2025. The fund’s quarter-end position value in Kymera Therapeutics rose by $297.15 million, a change that includes both trading activity and share price appreciation.
| Metric | Value |
|---|---|
| Price (as of market close 2026-02-17) | $84.84 |
| Market Capitalization | $6.70 billion |
| Revenue (TTM) | $43.73 million |
| Net Income (TTM) | ($295.12 million) |
Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on leveraging targeted protein degradation to address serious diseases with high unmet need. The company’s pipeline includes programs in immunology, oncology, and fibrosis, supported by a growing portfolio of proprietary technologies. Strategic emphasis on first-in-class therapies and partnerships with leading industry players position Kymera as an innovator in the protein degradation space.
It’s not surprising that a fund might lean into this stock. Kymera enters 2026 with what management calls an industry-leading oral immunology pipeline and roughly $1.6 billion in cash, pushing runway into 2029. Meanwhile, KT-621 is already in Phase 2b for atopic dermatitis and asthma, with Fast Track designation from the FDA and early data showing deep STAT6 degradation and biomarker improvements. And KT-579, targeting IRF5, is expected to enter Phase 1 this quarter, with data in the second half of the year. In other words, this is not a single-asset story.
Shares at $84.84 are up 130% over the past year, well ahead of the broader market, and within a portfolio already concentrated in oncology and metabolic biotech leaders measured in the billions, this position sits as a meaningful but not dominant allocation.
Ultimately, long-term investors should watch whether Phase 2b readouts confirm biologics-like efficacy with oral convenience. If the degrader platform delivers consistent clinical validation across indications, the multiple could expand further. If efficacy narrows versus incumbents, enthusiasm may cool quickly.
Before you buy stock in Kymera Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kymera Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 23, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BeOne Medicines Ag and Incyte. The Motley Fool recommends Kymera Therapeutics. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
